Filing Flows › TherapeuticsMD (TXMD) › Who owns the stock
Who owns TherapeuticsMD (TXMD) stock
42 funds reported TherapeuticsMD (TXMD) shares in their latest 13F filings, worth $8.7M in all. The largest holder is Rubric Capital Management LP ($2.6M). Last quarter 14 funds added to their stakes and 11 cut them.
Largest holders (13F)
| Fund | Shares | Value | Change | Quarter |
|---|---|---|---|---|
| Rubric Capital Management LP | 1,192,191 | $2.6M | unchanged | 2026-06-30 |
| Clearline Capital LP | 635,222 | $1.4M | unchanged | 2026-06-30 |
| Vanguard Capital Management LLC | 353,697 | $782K | unchanged | 2026-06-30 |
| Tejara Capital | 344,482 | $761K | decrease | 2026-06-30 |
| ADAR1 Capital Management, LLC | 342,447 | $757K | increase | 2026-06-30 |
| Vanguard Group | 397,056 | $647K | increase | 2025-12-31 |
| Renaissance Technologies LLC | 146,599 | $324K | increase | 2026-06-30 |
| Morgan Stanley | 129,217 | $286K | unchanged | 2026-06-30 |
| BlackRock | 115,145 | $254K | unchanged | 2026-06-30 |
| Geode Capital Management, LLC | 105,849 | $234K | decrease | 2026-06-30 |
| Citadel Advisors LLC | 86,095 | $190K | increase | 2026-06-30 |
| Vanguard Fiduciary Trust | 63,831 | $141K | unchanged | 2026-06-30 |
| State Street | 30,100 | $67K | unchanged | 2026-06-30 |
| XTX Topco | 21,246 | $47K | decrease | 2026-06-30 |
| Dimensional Fund Advisors LP | 19,719 | $44K | increase | 2026-06-30 |
TherapeuticsMD's latest quarter
TherapeuticsMD, Q2 2026: revenue $869K (-9% year over year), operating margin -93.9%, net earnings $155K, operating cash flow $779K. The chart follows the revenue to costs, profit and cash.
Questions
Who owns the most TXMD stock?
By the latest 13F filings: Rubric Capital Management LP ($2.6M); Clearline Capital LP ($1.4M); Vanguard Capital Management LLC ($782K); Tejara Capital ($761K); ADAR1 Capital Management, LLC ($757K).
What is the short interest in TXMD?
24,664 shares were sold short at the 2026-10-15 settlement, 4.23% of the float.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.